Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821267 | 0.83 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL25820244 | 0.80 | HTR2A (0.40) | HTR2AHTR2CHTR2BHRH4 | |
| SCHEMBL25820213 | 0.79 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL25820215 | 0.78 | HTR2A (0.40) | HTR2AHTR2CHTR2BHRH4 | |
| SCHEMBL25820200 | 0.78 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL25820228 | 0.76 | HTR2A (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL25820217 | 0.76 | HTR2A (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL23999681 | 0.75 | LIMK1 (0.36) | SIRT1LIMK1KDM4E | |
| SCHEMBL25820230 | 0.74 | ADRA1A (0.43) | HTR2AHTR2CHTR2BLIMK1 | |
| SCHEMBL25820198 | 0.74 | HTR2A (0.40) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | HTR2A 2819/4885HTR2C 2539/4885HTR2B 3066/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | HTR2A 2539/4885HTR2C 2111/4885HTR2B 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.